Initial Development Project Targets Predicting Flares in Patients Diagnosed with Atopic DermatitisFRIENDSWOOD, Texas, June 16 ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

Outcomes were evaluated among children born between April 1980 and June 2019 by using data from 12 observational birth ...

A Google search on “diet and eczema” may be more misleading than helpful, warns pediatric dermatologist Sandipan Dhar.

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

Arcutis Biotherapeutics has enrolled the first child in an open-label Phase II trial of Zoryve (roflumilast) for atopic ...

Castle Biosciences and SciBase join forces to create a predictive test for atopic dermatitis flare-ups. Read more here.

The Canine Atopic Dermatitis Treatment Market size is expected to experience a considerable valuation bump, from USD 1,182.60 million in 2024 to USD 1,620.50 million in 2034. The updated report points ...

EMA’s veterinary medicinal products committee recommends marketing authorization to Elanco’s Zenrelia to treat atopic dermatitis in dogs: Greenfield, Indiana Monday, June 16, ...

Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the ...